MedPath

SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED

Ownership
-
Established
1998-11-20
Employees
7K
Market Cap
-
Website
http://www.xhzy.com
Introduction

The company was founded in 1943 at the Jiaodong anti-Japanese base. It is the first chemically synthesized pharmaceutical company in New China. It is an important global production and export base for antipyretic analgesics, and an important domestic manufacturer of cardiovascular, anti-infective, neurological, and steroidal hormone drugs. The company is mainly engaged in the development, manufacture and sale of chemical raw materials, formulations and chemical products. The company's main products are “Xinhua” antipyretic and analgesic drugs, cardiovascular, anti-infective and central nervous system drugs. Corporate honors: Advanced grass-roots party organizations for provincial management enterprises, enterprises that focus on cultivating century-old brands, list of the top 1000 innovative Chinese enterprises, etc.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

387

NMPA:387

Drug Approvals

Isavuconazonium Sulfate for Injection

Product Name
注射用硫酸艾沙康唑
Approval Number
国药准字H20254347
Approval Date
May 27, 2025
NMPA

Icosapent Ethyl Soft Capsules

Product Name
二十碳五烯酸乙酯软胶囊
Approval Number
国药准字H20254286
Approval Date
May 27, 2025
NMPA

Icosapent Ethyl Soft Capsules

Product Name
二十碳五烯酸乙酯软胶囊
Approval Number
国药准字H20254287
Approval Date
May 27, 2025
NMPA

Ibuprofen Suspension Drops

Product Name
布洛芬混悬滴剂
Approval Number
国药准字H20254095
Approval Date
May 13, 2025
NMPA

Ibuprofen Suspension Drops

Product Name
布洛芬混悬滴剂
Approval Number
国药准字H20254094
Approval Date
May 13, 2025
NMPA

Aspirin Enteric-coated Tablets

Product Name
阿司匹林肠溶片
Approval Number
国药准字H20258068
Approval Date
Apr 24, 2025
NMPA

Memantine Hydrochloride Oral Solution

Product Name
盐酸美金刚口服溶液
Approval Number
国药准字H20253925
Approval Date
Apr 15, 2025
NMPA

Pregabalin Oral Solution

Product Name
普瑞巴林口服溶液
Approval Number
国药准字H20253926
Approval Date
Apr 15, 2025
NMPA

Tadalafil Tablets

Product Name
他达拉非片
Approval Number
国药准字H20258045
Approval Date
Mar 28, 2025
NMPA

Tadalafil Tablets

Product Name
他达拉非片
Approval Number
国药准字H20258046
Approval Date
Mar 28, 2025
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 39
  • Next

Clinical Trials

No trials found

News

Shandong Xinhua Pharma Gains Approval for Febuxostat Tablets in China

Shandong Xinhua Pharmaceutical's subsidiary, Shandong Zibo Xincat Pharmaceutical, has received approval from China's National Medical Products Administration for its febuxostat tablets.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.